Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

AUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 2023 BIO International Convention held June 5-8, 2023 in Boston and the Jefferies Healthcare Conference held June 7-9, 2023 in New York City.

Metadata
Provider: 
GlobeNewswire, Inc.GlobeNewswire, Inc.
Retrieved on: 
Wednesday, May 31, 2023
Information
Tags: 
LUMO, Jefferies, Conference, Pharmaceutical industry, Perfume
Geotags: 
AUSTIN, TX, US, NEW YORK CITY, BOSTON, NEW YORK, TEXAS
⚠ partially generated by AI ↴
Organisation: 
LUMOS PHARMA, LUMOS PHARMA, INC.
Summary
Key Points: 
  • AUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 2023 BIO International Convention held June 5-8, 2023 in Boston and the Jefferies Healthcare Conference held June 7-9, 2023 in New York City.
  • Lumos Pharma management will present and host one-on-one meetings at both conferences.
  • BIO International Convention: June 5th – 8th in Boston, MA
    Lumos Pharma Presentation – June 6th, 2:45 PM EDT
    Jefferies Healthcare Conference: June 7th – 9th in New York, NY
    Lumos Pharma Fireside Chat – June 9th, 12:45-1:10 PM EDT
    Management will host one-on-one meetings with investors on Friday, June 9th
    The webcast for the Jefferies Conference fireside chat will also be found on the Company’s website under Events & Presentations in the Investors & Media section.
  • Please contact your Jefferies salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team during the Jefferies Healthcare Conference or thereafter.



AUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 2023 BIO International Convention held June 5-8, 2023 in Boston and the Jefferies Healthcare Conference held June 7-9, 2023 in New York City. Lumos Pharma management will present and host one-on-one meetings at both conferences.

BIO International Convention: June 5th – 8th in Boston, MA

  Live Presentation: Lumos Pharma Presentation – June 6th, 2:45 PM EDT
  1x1 Meetings: Registrants may schedule 1x1s through the BIO International Convention portal
     

Jefferies Healthcare Conference: June 7th – 9th in New York, NY

  Live Presentation: Lumos Pharma Fireside Chat – June 9th, 12:45-1:10 PM EDT
  Webcast link: Here
  1x1 Meetings: Management will host one-on-one meetings with investors on Friday, June 9th
     

The webcast for the Jefferies Conference fireside chat will also be found on the Company’s website under Events & Presentations in the Investors & Media section. A replay will be available for 90 days thereafter. Please contact your Jefferies salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team during the Jefferies Healthcare Conference or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD subjects otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
[email protected]

Source: Lumos Pharma, Inc.


Primary Logo
Copyright: 
2023 GlobeNewswire, Inc.. All Rights Reserved.